Arena Pharmaceuticals (ARNA) is handing off one of its drug candidates to United Therapeutics (UTHR) in exchange for an eye-popping $800 million upfront payment, the company announced Thursday. The deal could ultimately be worth up to $1.2 billion.
United will receive most of the rights to ralinepag, which Arena has been testing for pulmonary arterial hypertension. The drug is currently in Phase 3 clinical trials.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
What if P3 trial results disappoint? Is this an $800m gamble or are there early indications that the drug will gain FDA approval?
This is what exactly Arena investors have been looking for. A win-win deal for both the companies. https://news.alphastreet.com/arena-pharmaceuticals-arna-stock-soars-on-agreement-with-united-therapeutics-uthr/